Borrelia burgdorferi Antibodies, IgG and IgM by Immunoblot (CSF)

Casandra

Casandra Test Code AR15636Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 0055260CPT Code 86617

Borrelia burgdorferi Antibodies, IgG and IgM by Immunoblot (CSF)

Also known as: LYME WBCSF

Clinical Use

Order Test

Use

The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate a central nervous system infection, suggesting the presence of Lyme neuroborreliosis. This qualitative immunoblot test differentiates between IgG and IgM antibodies to provide further diagnostic context. It is part of the workup for suspected Lyme neuroborreliosis but should not be used in isolation or without consideration of concurrent serum antibody testing and clinical symptoms.

Special Instructions

Do not order this test in the absence of clinical symptoms of Lyme neuroborreliosis or without concurrent serum antibody testing. The test is intended to supplement the workup of suspected acute Lyme neuroborreliosis cases. Specimens from New York state clients will be routed to a NY-approved laboratory since the test is not NY-approved.

Limitations

A negative result indicates the absence of antibodies unique to Borrelia burgdorferi, which is not suggestive of Lyme disease. Positive results should be correlated with clinical findings, considering potential contamination by blood or transfer of serum antibodies across the blood-brain barrier. IgM immunoblot is not recommended in chronic stages of Lyme disease. This is a laboratory-developed test and has not been cleared by the FDA.

Test Details